Varegacestat’s pivotal study reads out imminently.

Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.

ASH and SABCS approach.

The project has priority review, but deaths could raise eyebrows.

New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.

An in vivo Car-T produced a 100% response rate – in three patients.

Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.